A federal review board voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was slim. It is non-mandatory. The FDA has given no signal on whether it will act on the guidance. The move came after weeks of open hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could change how the agency handles a part of the wellness market that is growing very fast. Industry players are waiting to see if the FDA follows through on the vote. A spokesperson offered no fixed date for a follow-up. Wellness voices argue the change would open up access to products users find useful. Safety voices warn that looser rules could weaken safeguards across a fast-moving market. The committee vote only lays the groundwork for change, and the last word rests with the agency.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch